Skip to content
Menu

Twist Bioscience Corporation TWST

Full chart Compare
Set alert

Price alert · TWST

All alert types
104.75 USD -6.87 (-6.15%)

As ofNov 20, 2026, 11:42 AM EST

101.00 Day range 108.50
25.67 52-week range 219.71
YTD
+230.23%
1 year
+301.80%

5D -1.18 (-1.12%)

110120MonTueWedThuFri104.39
Market cap
7.14B
Revenue (ttm)
459.43M
Profit margin
-28.34%
EPS (ttm)
-2.08
Shares out
68.18M
Forward P/E
1708.56
YTD return
+230.23%
1-year return
+301.80%
50-day average
149.33
200-day average
94.23
Volume
1.01M
Avg volume
2.46M
Open
108.39
Previous close
111.62
Day's range
101.00 – 108.50
52-week range
25.67 – 219.71
Beta
2.22
Analysts
Buy
Price target
128.92 (+23.1%)
Earnings date
Feb 1, 2027

Key statistics

Enterprise value
7.46B
Price / sales
16.56
Price / book
8.52
Revenue growth
27.90%
Free cash flow
-55.86M
Total cash
581.91M
Total debt
109.98M
Return on equity
-19.13%
Short % of float
18.19%

Fundamental scorecard

6 of 25 checks passed on TWST’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TWST Revenue — quarterly 126.64M
TWST Net income — quarterly -20.62M
TWST EPS — quarterly -0.30

Earnings

TWST recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 1, 2027Dec 30, 2026-0.35———
Nov 12, 2026Sep 30, 2026-0.38707-0.32+0.07+17.33%
Aug 3, 2026Jun 30, 2026-0.50625-0.56-0.05-10.62%
May 4, 2026Mar 31, 2026-0.49-0.71-0.22-44.90%
Feb 2, 2026Dec 31, 2025-0.48-0.50-0.02-4.17%
Nov 14, 2025Sep 30, 2025-0.50-0.45+0.05+10.00%

Upgrades / downgrades

TWST analyst upgrades and downgrades
DateFirmActionFromTo
Oct 13, 2026TD CowenmainBuyBuy
Oct 12, 2026Canaccord GenuitymainBuyBuy
Oct 8, 2026Jefferiesinit—Hold
Oct 7, 2026BarclaysmainOverweightOverweight
Oct 1, 2026GuggenheimmainBuyBuy
Sep 29, 2026Leerink PartnersmainOutperformOutperform

About Twist Bioscience Corporation

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications. It provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on TWST — it syncs with the Stock Master app.

Insider holders

TWST insider holders
InsiderRelationLatest transactionDateShares held
CHAN NELSON CDirectorStock Award(Grant)Feb 4, 202633,251
CHESS ROBERT BRUCEDirectorConversion of Exercise of derivative securityAug 6, 202663,612
CHO DENNISOfficerStock Award(Grant)Nov 15, 202687,283
CRANDELL KEITH L.DirectorStock Award(Grant)Feb 4, 2026103,618
FINN PATRICK JOHNPresidentStock Award(Grant)Nov 15, 2026239,367
GREEN PAULAOfficerStock Award(Grant)Nov 15, 2026128,145

Institution ownership

TWST institution ownership
Holder% heldSharesValueReported
FMR, LLC15.46%9,695,5181.08BSep 29, 2026
Blackrock Inc.10.18%6,386,116712.82MSep 29, 2026
Price (T.Rowe) Associates Inc9.70%6,084,852679.19MSep 29, 2026
ARK Investment Management, LLC5.42%3,398,057379.29MSep 29, 2026
Vanguard Portfolio Management LLC4.98%3,122,452348.53MSep 29, 2026
State Street Corporation4.81%3,017,072336.77MSep 29, 2026

Fund ownership

TWST fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.99%1,874,473209.23MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.73%1,714,174191.34MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.16%1,357,205151.49MJun 29, 2026
ARK ETF Trust-ARK Innovation ETF2.15%1,346,052150.25MOct 30, 2026
ARK ETF Trust-ARK Genomic Revolution ETF1.91%1,194,813133.37MOct 30, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.88%1,177,281131.41MSep 29, 2026